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Abstract
Propagation of multidrug‐resistant Pseudomonas aeruginosa, which causes endemic noso‐
comial infections, has become a major concern in various parts of the world. In patients 
with cystic fibrosis, a major cause of death is respiratory tract infections with antibiotic‐
resistant P. aeruginosa. This condition has prompted medical research aimed at develop‐
ing effective prophylaxis and treatments that do not rely on conventional antimicrobial 
agents. The pathogenesis that results in cytotoxicity and mortality in immunocompro‐
mised patients infected with P. aeruginosa is associated with the type III secretion sys‐
tem of this bacterium. Clinical isolates that are cytotoxic and drug‐resistant are involved 
in acute exacerbation of chronic infectious diseases. The P. aeruginosa V‐antigen PcrV, 
a Yersinia V‐antigen LcrV homolog, is involved as an indispensable component in the 
translocational process of type III secretory (TTS) toxins. Vaccination against PcrV 
ensures survival of infection‐challenged mice and decreases lung inflammation and 
injury. Furthermore, anti‐PcrV IgG can inhibit translocation of TTS toxins. These observa‐
tions support the hypothesis that anti‐PcrV strategies have the potential as nonantibiotic 
immune strategies for preventing aggravation of P. aeruginosa infections in patients with 
cystic fibrosis.
Keywords: cystic fibrosis, exoenzyme, PcrV, Pseudomonas aeruginosa, type III secretion 
system, V‐antigen
1. Introduction
Propagation of multidrug‐resistant Pseudomonas aeruginosa (MDR‐PA) has become a serious 
concern in various parts of the world [1–4]. Recent outbreaks of extensively drug‐resistant 
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P. aeruginosa (XDR‐PA) are threatening to increase XDR‐PA colonization of immunocompro‐
mised and artificially ventilated patients because efficacious antimicrobial choices against 
XDR‐PA are limited [3–5]. In patients with cystic fibrosis (CF), a major cause of death is respi‐
ratory tract infections with P. aeruginosa. This condition has led to medical research on the 
development of effective prophylaxis and treatments that do not rely on conventional antimi‐
crobial agents [6]. Furthermore, recent reports have suggested that XDR‐PA strains appear to 
have a greater ability to promote bacteremia and sepsis [7]. Therefore, the pathogenic mecha‐
nisms that are responsible for this infection are important for protecting patients from the 
lethal consequences of these infections.
The pathogenesis responsible for mortality in P. aeruginosa pneumonia is associated with the 
development of septic shock and multiple organ failure. This is because certain P. aeruginosa 
strains have the ability to cause necrosis of the lung epithelium and disseminate into the circu‐
lation [8]. Advances in genomic analysis and cellular microbiology have shown that damage 
to the lung epithelium is associated with expression of toxins. These toxins are directly trans‐
located into eukaryotic cells through the type III secretion system (TTSS) of P. aeruginosa [9]. 
Unlike classic type I and type II secretion systems, the newly identified TTSS, through which 
bacteria directly transfer their toxins from the bacterial cytosol to the eukaryotic cell cytosol, 
were discovered in most pathogenic Gram‐negative bacteria (Figure 1) [10]. Four type III secre‐
tory (TTS) toxins, called ExoS, ExoT, ExoU, and ExoY, have been identified in P. aeruginosa [11, 
12]. ExoS is the 49‐kDa form of exoenzyme S, which is a bifunctional toxin that has ADP‐ribo‐
syltransferase and GTPase‐activating protein (GAP) activities [13]. ExoS disrupts endocytosis, 
Figure 1. Toxin secretion systems in Gram‐negative bacteria. In the types I and II secretion systems, bacteria secrete 
toxins into the extracellular space (left side of figure). As one example, secreted toxins are captured by surface receptors 
on the eukaryotic cell membrane and are then transferred to the cytosol. In the types III and IV secretion systems, bacteria 
secrete toxins directly into the cytosol of target eukaryotic cells through their secretion apparatus (right side of the 
figure). The mechanism whereby the secreted toxins are transferred to the eukaryotic cell cytosol is called translocation.
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the actin cytoskeleton, and cellular proliferation. ExoT, which is a 53‐kDa form of exoenzyme 
S with 75% sequence homology to ExoS, also exerts GAP activity and interferes with cell mor‐
phology and motility [13–15]. ExoY is a nucleotidyl cyclase that increases intracellular levels 
of cyclic adenosine and guanosine monophosphates, resulting in the formation of edema [12]. 
ExoU exhibits phospholipase A
2
 activity activated by host cell ubiquitination after transloca‐
tion. ExoU is a major pathogenic cytotoxin that causes alveolar epithelial injury and necrosis 
of macrophages [16–19].
In this review, we summarize the TTSS of P. aeruginosa and its association with CF. We also 
review the development of immune therapies, including passive and active immunization 
against the TTSS‐associated virulence of P. aeruginosa.
2. Cytotoxic or invasive P. aeruginosa strains
In most acute clinical manifestations of P. aeruginosa infection, severe pneumonia occurs in 
patients under ventilatory management and in immunocompromised patients [2, 3]. Patients 
with severe P. aeruginosa pneumonia frequently develop sepsis and subsequent multiorgan 
failure [7].
In the mid‐1990s, researchers investigating P. aeruginosa reported that the strains expressing 
ExoS (49‐kDa type exoenzyme S) had low cytotoxicity to eukaryotic cells, whereas the strains 
that did not express ExoS had strong cytotoxicity [20, 21]. Therefore, at that time, P. aeruginosa 
strains were classified as either a cytotoxic exoS− type or an invasive exoS+ type, depending 
on the genotypes of the 49‐kDa exoenzyme S [20]. The 53‐kDa exoenzyme S (ExoT) was dis‐
covered as a gene product that was distinct from ExoS [14, 15]. However, because cytotoxic 
exoS− type‐ and invasive exoS+ type‐strains both possessed ExoT, the mechanism for cytotoxic 
virulence could not be explained solely on the basis of possessing the ExoT gene. Therefore, 
the mechanism whereby the cytotoxic characteristics of exoS−exoT+ type‐strains develop is 
unknown. In 1997, a new cytotoxin, ExoU, was identified [16]. P. aeruginosa strains that do not 
have exoU always possess exoS. Therefore, the genotype of cytotoxic strains is exoS−exoT+exoU+ 
and the genotype of invasive strains is exoS+exoT+exoU− [20, 21]. While searching for major 
cytotoxins in P. aeruginosa, P. aeruginosa exoenzymes were found to translocate directly into 
the eukaryotic cytosol through the TTS mechanism [22]. Among the four TTS cytotoxins, 
ExoS, ExoT, ExoU, and ExoY, P. aeruginosa clinical isolates that cause severe sepsis and mor‐
tality express TTS ExoU [16, 23–25]. After discovery of ExoU, studies showed the enzymatic 
action of phospholipase A
2
, which is activated by a eukaryotic cell factor after translocation 
into the eukaryotic cell cytosol [17–19].
3. Genomic analyses of P. aeruginosa strains
The whole genome sequencing project by the Pseudomonas Genome Project was completed for 
the P. aeruginosa strain PAO1 in 2000 [26]. Since this time, comparative genomics is currently 
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on‐going between the PAO1 reference strain and various clinical isolates of which the char‐
acteristics differ from PAO1 (Figure 2). In this research field, the major question is how much 
do the strains differ from each other at the gene level, especially between strains isolated from 
patients with acute infections and strains isolated from chronically infected patients with CF. 
The genetic mechanisms underlying multidrug resistance are also of major interest in these 
comparative genomic studies.
The clinical isolate UCBPP‐PA14 is cytotoxic and is similar to the laboratory strain PA103 
UCBPP‐PA14 that has the TTS phenotype ExoS−ExoT+ExoU+ExoY−, whereas invasive PAO1 
is ExoS+ExoT+ExoU−ExoY+ [16, 20]. Therefore, genomic analysis of UCBPP‐PA14 was con‐
ducted to identify their phenotypic differences. As a result, two pathogenicity islands 
that do not exist in PAO1 were discovered in the UCBPP‐PA14 genome [27]. Thereafter, 
researchers found that clinical strains containing P. aeruginosa pathogenicity island‐2 
(PAPI‐2) and exoU display the cytotoxic phenotypes that are responsible for acute lung 
injury in animal models [16, 27]. Concurrently, strains harboring PAPI‐2 and exoU were 
found to have deletional mutation of the exoS gene, which creates the exoS− genotype in 
PA103 and UCBPP‐PA14 [27].
Figure 2. The PAO1 reference strain genome and its pathogenic gene configuration. The P. aeruginosa strain PAO1 
possesses 5570 genes in its 6.3‐Mb circular genome. The exoenzyme S regulon is a gene cluster (25.7 kb) for type III 
secretion. Type III secretory toxin genes, such as exoS, exoT, and exoY, are scattered throughout the genome. The P. 
aeruginosa exoU gene, which is located in an insertional pathogenic gene cluster in pathogenicity island‐2 (PAPI‐2), was 
discovered in the UCBPP‐PA14 virulent clinical strain.
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4. The type III secretion system of P. aeruginosa
4.1. Components of the type III secretion system and the exoenzyme S regulon
The TTSS is composed of the following: (1) secretion apparatus (injectisome), (2) translocators, (3) 
a set of secreted toxins, and (4) regulatory components [28]. In the P. aeruginosa genome, a patho‐
genic gene cluster called the exoenzyme S regulon encodes the genes for regulation, secretion, 
and translocation of the TTSS [9, 11] (Figure 3). In the exoenzyme S regulon, the exsCBA operon 
encodes the transcriptional activator protein ExsA, which regulates expression of exoenzyme S 
and its co‐regulated proteins (Figure 4) [11]. Four TTS toxins, ExoS, ExoT, ExoU, and ExoY were 
identified in P. aeruginosa (Table 1) [11, 12, 16]. The genes for these TTS toxins are scattered in the 
genome [26]. In contrast, exoU, which is located in the insertional gene pathogenic cluster PAPI‐2, 
is present with its chaperone protein gene spcU only in the genomes of cytotoxic strains, such as 
PA103 and UCBPP‐PA14 [16, 27, 29].
4.2. The pcrGVHpopBD translocation operon
One operon in the exoenzyme S regulon, called pcrGVHpopBD, encodes five proteins associ‐
ated with translocational processes for TTS toxins [11]. These proteins are PcrV, PopB, and 
PopD, and their chaperones are PcrG and PcrH. PcrV, which is the P. aeruginosa V‐antigen, 
is a cap structure component on the tip of the injection needle formed by PscF in the secre‐
tion apparatus [30] (Figure 5). The genetic organization for the exoenzyme S regulon shares 
Figure 3. Genomic structure of the exoenzyme S regulon. The type III secretion regulatory region (25.5 kb), found as a 
gene cluster, was named the exoenzyme S regulon. The exoenzyme S regulon comprises five operons, including 36 genes 
for transcription (exsA‐exsD), genes encoding the secretion apparatus (pscB‐pscU), and others encoding translocation‐
related proteins (pcrGVHpopBD). The exsCBA operon encodes the transcriptional activator ExsA protein, which regulates 
expression of exoenzyme S and co‐regulated proteins.
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the most homology with the Yersinia Yop virulon [31]. Yersinia LcrV has been reported to 
be a molecular target competing with TTSS virulence. Similarly, P. aeruginosa PcrV also is a 
molecular target that can compete with TTSS virulence in P. aeruginosa [32, 33]. This competi‐
tion with TTSS virulence will be discussed later in this review.
Figure 4. Type III secretion regulation in P. aeruginosa by the ExsA transcriptional activator. The ExsA transcriptional 
activator protein activates five operons in the exoenzyme S regulon via five ExsA binding motifs “TxAAAAxA”. ExoT, 
ExoU, and ExoY were identified in P. aeruginosa. Genes for ExoS, ExoT, and ExoY are scattered in the genome. The orf1 
gene, which encodes a chaperone protein for ExoS, is next to exoS. The exoU gene, which is located in the insertional gene 
pathogenic cluster PAPI‐2, is present with its chaperone protein gene spcU only in the genomes of cytotoxic strains, such 
as PA103 and UCBPP‐PA14.
Toxins Size (kDa) Enzymatic activity Action
ExoS 49 FAS‐dependent 
ADP‐ribosyltransferase
Antiphagocytosis, 
inhibition of endocytosis
ExoT 53 Small GTPase activating 
protein activity
Inhibition of tissue repair
ExoU 74 Phospholipase A2 Cytotoxin, lipid 
degradation
ExoY 42 Adenylate cyclase Edema formation, 
anti‐inflammatory
Table 1. Type III secretory toxins in P. aeruginosa.
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4.3. Yersinia V‐antigen LcrV and P. aeruginosa PcrV
Historically, Yersinia LcrV has been referred to as the Yersinia V‐antigen. Approximately 50 
years ago in the UK, Burrows et al. reported that Yersinia V‐antigen was an antigen substance 
associated with the pathogenic toxicity [34–38] of this bacterium. They found that only Y. pes‐
tis, with the antigenic factor they called the V‐antigen, induced immunity in a mouse model 
of infection [34–38]. In 1986, the gene encoding the LcrV V‐antigen, lcrV, was cloned from the 
Low‐calcium response (LCR) operon of the Y. pestis pCD1 plasmid [39]. A genetic mutation 
experiment then showed that LcrV is essential for translocation of the toxin [32]. Additionally, 
antibodies against LcrV were reported to be capable of blocking transfer of the toxin [32]. As 
well as Yersinia LcrV in the TTSS, P. aeruginosa PcrV is essential for transition of the TTSS toxin, 
and the antibody against PcrV can block transition of the TTS toxin [33]. PcrV might play a role 
Figure 5. The type III secretory apparatus of P. aeruginosa. The P. aeruginosa type III secretory apparatus comprises many 
protein components as follows: a cap component, PcrV; a needle component, PscF; an outer ring component, PscC; and 
basal components, including PscJ, ATPase PscN, and others. Four type III secretory toxins, ExoS, ExoT, ExoU, and ExoY, 
are injected directly into the cytosol of target eukaryotic cells through the type III secretory apparatus. Translocated 
toxins are activated by specific eukaryotic cell cofactors. Following activation, ADP‐ribosyltransferase activity is shown 
by ExoS, whereas ADP‐ribosyltransferase and GTPase‐activating protein activity is shown by ExoT. Activated ExoU has 
phospholipase A
2
 activity, and ExoY exhibits adenylate cyclase activity.
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in connecting the needle rod (composed of PscF) to the pore (formed with PopB/PopD) on the 
eukaryotic cell membrane. Indeed, electron microscopy has successfully visualized V‐antigens 
as cap structures on the mushroom needle tip portion of the protein [30]. Specific blocking 
antibodies against the V‐antigen also block translocated toxin from binding to the top part of 
the cap structure [32, 40].
5. P. aeruginosa type III secretory toxins
5.1. ExoS and ExoT
In the late 1970s, P. aeruginosa exoenzyme S was discovered as an adenosine diphosphate 
ribosyltransferase that was distinct from exotoxin A [41, 42]. However, in the mid‐1990s, exo‐
enzyme S activity was determined to be the result of two highly homologous toxins, termed 
ExoS (49‐kDa exoenzyme S) and ExoT (53‐kDa exoenzyme S), which are encoded in two 
separate portions of the P. aeruginosa genome [14, 15]. ExoS and ExoT were also found to be 
secreted by the TTS mechanism [15, 22].
5.1.1. ADP‐ribosyltransferase activity
ExoS and ExoT are two immunologically indistinguishable proteins that co‐fractionate with 
exoenzyme S activity [14]. ExoS and ExoT encode proteins of 457 and 453 amino acids, respec‐
tively, and share 75% amino acid identity. ExoT possesses approximately 0.2% of the ADP‐
ribosyltransferase activity of ExoS [14, 15]. ExoT diminishes motility of macrophages and 
phagocytosis, at least in part through disrupting the eukaryotic cellular actin cytoskeleton, 
and also blocks wound healing [43, 44]. The ExoS carboxyl terminal catalyzes transfer of the 
ADP‐ribose moiety of nicotinamide adenine dinucleotide to a number of different proteins, 
including the intermediate filament protein, vimentin [45–47].
5.1.2. GTPase‐activating protein activity
The amino terminal domains of ExoS and ExoT have been characterized as GAPs of Rho 
GTPases [48]. The Rho GAP activity of ExoS stimulates reorganization of the actin cytoskeleton 
by inhibiting Rac and Cdc42, and induces formation of actin stress fibers by inhibiting Rho 
[49]. These domains, which include catalytic arginines, share sequence homology with not only 
Yersinia YopE and Salmonella SptP, but also with mammalian Rho GAP proteins, such as hsp‐
120GAP, hsNF1, dmGAP1, and sclRA1. Biochemical studies have shown that ExoT possesses 
GAP activity for RhoA, Rac1, and Cdc42, and interferes with Rho signal transduction pathways, 
which regulate actin organization, exocytosis, cell cycle progression, and phagocytosis [50, 51].
5.2. ExoU
A specific isogenic mutant of the cytotoxic P. aeruginosa strain PA103, which does not have ExoS 
and is genetically modified to lack ExoT, is still cytotoxic in vitro. This mutant causes epithelial 
injury in vivo, indicating that another cytotoxin is responsible for the observed pathology [16, 
17]. In 1997, ExsA‐activated ExoU was discovered to be a major virulence factor causing lung 
injury and the exoU gene was cloned from the cytotoxic strain PA103 [16]. A region downstream 
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of exoU encodes a small 15‐kDa protein named SpcU, which functions as a chaperone for ExoU 
[29]. ExoU is a TTS protein of P. aeruginosa that is necessary for epithelial cell cytotoxicity in vitro 
and virulence in a mouse model of pneumonia [16].
5.2.1. Patatin‐like phospholipase A
2
 activity
ExoU contains a potato patatin‐like phospholipase A (PLA) domain [17]. Patatin is a member 
of a multigene family of vacuolar storage glycoproteins with lipid acyl hydrolase and acyl 
transferase activities. Alignment of ExoU, potato patatin, and human PLA2 shows three highly 
conserved regions in the ExoU amino acid sequence as follows [17]: (1) a glycine‐rich nucle‐
otide binding motif, GXGXXG/A (position 111–116 in ExoU); (2) a serine‐hydrolase motif, 
which includes a serine active site for cPLA2, GXSXG/S (position 140–144 in ExoU); and (3) an 
active site motif containing aspartate for cPLA2, DGG/A (position 344–347 in ExoU) (Figure 6).
Figure 6. Enzymatic activity and consensus motifs in ExoU. P. aeruginosa ExoU, a major factor causing cytotoxicity 
and epithelial injury in the lungs, contains a patatin domain that catalyzes membrane phospholipids through its 
phospholipase A
2
 activity. Homology in the amino acid sequence, with a catalytic dyad in the primary structure, is found 
among patatin, mammalian phospholipase A
2
 (cPLA
2
‐α and iPLA
2
), and ExoU. FFA: free fatty acids.
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5.2.2. Phospholipase A
2
 activity and acute lung injury
Site‐directional mutations in the predicted catalytic site of ExoU cause a loss of lysophospho‐
lipase A activity [52]. Airspace instillation of virulent P. aeruginosa expressing ExoU causes 
acute lung injury and death in infected mice [53]. However, airspace instillation of isogenic 
mutants secreting catalytically inactive ExoU is non‐cytotoxic and this does not cause acute 
lung injury or death in these mice [53]. Therefore, virulent P. aeruginosa causes acute lung 
injury, with concomitant sepsis and mortality, via cytotoxic activity derived from the patatin‐
like phospholipase domain of ExoU. Cells targeted by ExoU through the TTSS are not only 
epithelial cells, but also macrophages [54]. Through the TTSS, ExoU is activated after its trans‐
location into the cytosol of eukaryotic cells [55–57]. Ubiquitin and ubiquitin‐modified pro‐
teins are associated with the activation of ExoU [18, 19].
5.3. ExoY
ExoY has adenylate cyclase activity and is secreted by the TTS mechanism [12]. The pri‐
mary ExoY sequence shares homology with sequences of the extracellular adenylate 
cyclases of Bordetella pertussis (CyaA), Bacillus anthracis (EF), and Y. pestis insecticidal toxin 
[12]. An unknown eukaryotic cell factor, distinct from calmodulin, enhances recombinant 
ExoY catalysis. Infection of eukaryotic cells with P. aeruginosa that produce catalytically 
active ExoY results in an elevation of intracellular cAMP and morphological changes in 
cells. ExoY increases the permeability of lung endothelial cells and alters Chinese hamster 
ovary cell morphology but does not result in acute cytotoxic responses. Ninety percent of 
clinical isolates that are tested show the presence of the exoY gene in DNA hybridization 
experiments [12]. ExoY production may play a role in protecting the bacterium from local 
phagocytic cells [58].
6. Cystic fibrosis and P. aeruginosa type III secretion
6.1. P. aeruginosa pneumonia and cystic fibrosis
Respiratory infections with P. aeruginosa are the major causes of morbidity and mortality in 
individuals with CF. P. aeruginosa isolates from newly infected patients with CF resemble 
those from acutely infected non‐CF patients, and have a number of virulence factors includ‐
ing flagella, pili, pyocin, pyoverdin, and the TTSS [59, 60]. Expression of these virulence fac‐
tors is considered to be essential for successful development of infection at an early stage of 
infection in patients with CF. However, at the chronic stage of infection, triggered by high 
selective pressure in CF lungs and by antibiotic treatments, P. aeruginosa gradually gener‐
ates genotypes and phenotypes that are specially adapted to the lungs in CF. These include 
overproduction of alginate (mucoid phenotype), loss of lipopolysaccharide O‐antigen compo‐
nents, loss of motility, resistance to antibiotics, virulence factor loss, and adapted metabolism 
[61]. These changes might be essential for P. aeruginosa to facilitate evasion of the host defense 
mechanisms and immune surveillance [62].
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6.2. Epidemiological studies of isolates from patients with cystic fibrosis
In our epidemiological study that analyzed clinical isolates, there was a subset of isolates that 
displayed the TTS phenotype ExoS−ExoU− with extensive drug‐resistant characteristics [63]. 
Most of these isolates were from chronic infections in patients with CF. Therefore, clinical 
isolates of P. aeruginosa are classified into three subgroups depending on their ExoS and ExoU 
phenotypes. ExoS+ExoU− strains are invasive and cause infections in burns tissues, whereas 
ExoS−ExoU+ strains are cytotoxic and cause acute pneumonia and sepsis. Most strains isolated 
from chronic infections in CF patients are ExoS−ExoU− (Figure 7). P. aeruginosa strains that 
are isolated from acutely infected patients show positive phenotypes for TTS proteins (ExoS, 
ExoU, and PcrV) and the positive O‐antigen phenotype. However, strains that are isolated 
from chronic infections of patients with CF are frequently the O‐antigen phenotype (−), TTS 
protein phenotypes (−), and the mucoid phenotype (+) with increased antibiotic resistance 
(Figure 8). Recent studies have shown that TTSS production, as well as other virulence factors, 
such as flagella, pili, pyocin, and pyoverdine, are attenuated in many isolates from chroni‐
cally infected patients with CF [64–66]. The results of several studies that investigated the 
relationship between CF clinical isolates and the TTSS in P. aeruginosa are shown in Table 2 
[61, 67–71]. Two of the six studies were longitudinal and followed the same patients with CF. 
Additionally, four studies performed genotype analysis on strains, and five others performed 
immunoblot analysis of TTS proteins. Findings from these epidemiological studies suggest 
that CF isolates from children are more virulent with a positive TTSS phenotype than isolates 
that are recovered from adults. These studies also suggest that isolates from initial infections 
are more virulent than isolates from subsequent infections. The ratio between ExoS+ExoU− 
and ExoS−ExoU+ differed in each study. However, a more recent report from Hu et al. showed 
that 7 isolates among 40 in total from subsequently occurring infections were ExoU+ [71]. 
These findings suggest the potential pathogenic involvement of ExoU‐associated virulence, 
even in patients with CF.
Figure 7. Type III secretory toxin phenotypes in P. aeruginosa clinical isolates. P. aeruginosa clinical isolates can be 
classified into three subgroups depending on their ExoS and ExoU phenotypes. ExoS(+)ExoU(−) stains are invasive and 
cause infections in burnt tissue, whereas ExoS(−)ExoU(+) strains are cytotoxic and cause acute pneumonia and sepsis. 
Most strains that are isolated from chronic infections in patients with cystic fibrosis are ExoS(−)ExoU(−).
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6.3. Type III secretion and cystic fibrosis isolates
Most studies have reported that the proportion of P. aeruginosa strains secreting TTS proteins 
decreases over the duration of P. aeruginosa infection. Jain et al. showed a significant inverse 
correlation between the percentage of TTS proteins and the duration of P. aeruginosa infection 
[67]. They also reported an association between the proportion of TTS protein‐secreting iso‐
lates and a decline in the rate of forced expiratory volume in 1 s in patients who still harbor at 
least some TTS‐positive isolates. Other reports that investigated the genotype and phenotype 
of the TTSS showed that all P. aeruginosa strains harbor at least some TTSS genes (exoS, exoT, 
exoU, exoY), regardless of the expression of TTS proteins (ExoS, ExoT, ExoU) [66, 69–71]. This 
suggests that the TTSS regulon may remain intact and the expression of TTSS can be revers‐
ible. There are other variants called rough small‐colony variants in P. aeruginosa, and these 
have been isolated from chronically infected patients with CF [72, 73]. These variants are 
hyperpiliated and hyperadherent, and differ from the mucoid phenotype in their secretion 
of TTS proteins. Their remarkably high resistance to several antibiotic classes enables their 
persistence in the lungs in CF.
6.4. Comparative genome studies on recent P. aeruginosa isolates
Comparative genomics on the reference PAO1 strain and isolates from patients with CF are 
on‐going. In 2003, two comparative studies between CF isolates and PAO1 were reported. 
These studies demonstrated that clinical strains do not express TTSS, whereas most of them 
that are isolated from chronic infections possess this gene cluster [74, 75]. Additionally, these 
studies show that 10% of genes in CF isolates do not exist in the PAO1 genome, and half of 
them are newly identified genes.
Figure 8. Phenotypic variation in P. aeruginosa clinical isolates. P. aeruginosa strains that are isolated from acutely infected 
patients are positive for type III secretory proteins, such as ExoS, ExoU, and PcrV, and are O‐antigen positive. In contrast, 
strains that are isolated from chronic infections in patients with cystic fibrosis are frequently O‐antigen‐negative and 
type III secretory protein‐negative, but are mucoid with increased antibiotic resistance.
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Year Author Reference CF clinical 
isolates, n
TTSS secretion 
(+), n (%)
Exoenzyme genotype, n Exoenzyme phenotype, n (% positive by 
genotype)
S T Y U S T Y U
2000 Dacheux 
et al.
[69] 29 8 (27.5%) 28 28 28 3 8 (28.6) 8 (28.6) NA 0 (0)
2004 Jain et al. [61] 235 (CI, 
children)
40 (18%) NA NA NA NA 35 (88) 40 (100) NA 2 (5)
200 (CI, adults) 8 (4%) 8 (100) 8 (100) NA 0 (0)
35 (NI) 17(49%) 17 (100) 17 (100) NA 0 (0)
2005 Lee et al. [68] 7 5 (71.4%) 
(initial)
7 NA NA 0 5 (71.4) NA NA 0 (0)
3 (42.8%) 
(subsequent)
6 NA NA 1 2 (28.6) NA NA 1 
(14.3)
2007 Wareham 
et al.
[70] 75 39 (52%) 66 75 74 12 NA NA NA 9 (75)
2008 Jain et al. [67] 1299 (CI, 
children)
29.1% NA NA NA NA NA NA NA NA
1217 (CI, adult) 11.5%
135 (NI) 45.2%
2013 Hu et al. [71] 52 (initial) 43 (82.7%) 44 NA NA 8 36 (82) NA NA 7 (88)
40 (subsequent) 26 (65%) 33 NA NA 7 19 (58) NA NA 7 (100)
Table 2. Studies on the relationship between cystic fibrosis and type III secretion in P. aeruginosa.
Anti‐PcrV Immunization for Pseudomonas aeruginosa Pneumonia in Cystic Fibrosis
http://dx.doi.org/10.5772/intechopen.69767
171
Recent reports have indicated that the combination of carbapenem and fluoroquinolone resis‐
tance and the presence of the gene encoding the TTSS ExoU effector in P. aeruginosa are the 
strongest predictors of development of pneumonia [76–78]. Further investigations have sug‐
gested that the fluoroquinolone‐resistant phenotype and the exoU+ genotype of P. aeruginosa 
cause poor clinical outcomes in patients with P. aeruginosa pneumonia [76–79]. Several genome 
sequence analyses of small colony variants of P. aeruginosa have been reported recently [80–85]. 
These studies showed multifactorial antibiotic‐resistance mechanisms, such as overexpression 
of efflux mechanisms, LPS modification, and a drastic downregulation of the Pseudomonas 
quinolone signal quorum‐sensing system. These reports suggest that, over the last 15 years, 
wide‐spread global carbapenem and fluoroquinolone use has rapidly enhanced propagation 
of virulent and drug‐resistant P. aeruginosa strains.
7. Anti‐PcrV strategies in P. aeruginosa infections
Recent outbreaks of XDR‐PA are threatening to increase colonization by MDR‐PA in immu‐
nocompromised patients because efficacious antimicrobial choices are extremely limited. 
Therefore, this situation requires development of new prophylactic or therapeutic strategies 
that do not rely on conventional antimicrobial agents [86, 87].
7.1. Active and passive immunization against P. aeruginosa PcrV
The first experimental trial on immunotherapy against the TTSS of P. aeruginosa was per‐
formed using E. coli‐derived recombinant PcrV protein to actively immunize mice [33]. In 
this experiment, the immunized mice survived lethal challenge infections with P. aeruginosa 
pneumonia. Together with the active immunization trial, passive immunization was carried 
out in mice with a purified protein A binding γ‐globulin fraction, which was separated from 
the sera of rabbits that were actively immunized with recombinant PcrV [30]. In this series, 
the immunized mice survived pulmonary administration of a lethal dose of P. aeruginosa. A 
correlation between the survival rate of the mice and the dose of the polyclonal anti‐PcrV anti‐
body was found. The effects of this polyclonal anti‐PcrV antibody were later tested in various 
animal models of burns and chronic bacterial pneumonia [88, 89].
The mechanism responsible for the positive effect of the polyclonal anti‐PcrV antibodies, in 
terms of whether the effect depends on the Fc‐portion of the antibody, was investigated. The 
anti‐PcrV polyclonal antibody F(ab)′
2
 was tested in a rabbit model, and the same effect as whole 
IgG was confirmed [90]. This finding strongly suggests that the prophylactic and therapeutic 
effects of anti‐PcrV polyclonal antibodies are derived by blocking the action involved in the 
pathogenicity of the antigen. Monoclonal antibody screening on normal mouse hybridomas 
was then performed and the clone mAb166 was discovered as the strongest TTSS blocker [40]. 
The clone mAb166 displayed equivalent therapeutic and prophylactic effects to those of the 
anti‐PcrV polyclonal antibody [40, 91, 92]. The mAb166 Fab fragment also conferred the same 
therapeutic effect as the original whole IgG in P. aeruginosa pneumonia [85]. In particular, 
mAb166 exerted a strong therapeutic effect following airway administration of P. aeruginosa 
in a pneumonia model in rats [93]. By using this mAb166 antibody as a template with the 
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bacteriophage gene shuffling recombination technology, the US venture company KaloBios 
Inc. started a project to create a humanized anti‐PcrV antibody. Consequently, KB001‐A was 
developed as a humanized monoclonal antibody [94]. This antibody underwent phase I and 
phase II clinical trials in the USA and France [95, 96].
7.2. Immunization against PcrV in immunocompromised models
Active immunization with PcrV was examined in immunocompromised mice that were pre‐
treated with cyclophosphamide [97]. Cyclophosphamide treatment induced immunosup‐
pression in the mice, decreased immunity against P. aeruginosa, and decreased the lethal dose 
of P. aeruginosa. In this study, five truncated PcrV fragments and full‐length‐PcrV were tested 
as vaccine candidates in a mouse model of P. aeruginosa pneumonia. Acute systemic infec‐
tion was introduced by intraperitoneal injection of a lethal dose of P. aeruginosa in this mouse 
model [97]. This study showed that active immunization with either full‐length PcrV
1–294
 or 
PcrV
139–294
, both of which contain the 
PcrV144–257
 blocking epitope region of monoclonal anti‐PcrV 
IgG mAb166, successfully protected the immunocompromised mice from lethal P. aeruginosa 
infection. This finding suggested that the anti‐PcrV strategy might be effective in neutropenic 
conditions in which human patients frequently develop P. aeruginosa infections.
The intravenous immunoglobulin (IVIG) was recently shown to confer significant protection 
against lethal infection with virulent P. aeruginosa [98, 99]. The effect of administrating 2.5 mg 
of IVIG was comparable with that of administrating 10 µg of specific anti‐PcrV polyclonal 
IgG. The mechanism of protection is likely to involve the synergic action of anti‐PcrV titers 
and some surface antigen to block the TTSS‐associated virulence of P. aeruginosa [98]. There 
is considerable variation in anti‐PcrV titers in adult subjects without any obvious history of 
infection with P. aeruginosa [100]. IVIG extracted from high anti‐PcrV titer human sera confers 
protective effects in a mouse model of lethal P. aeruginosa pneumonia [101]. These results sug‐
gest that, not only monoclonal strategies against PcrV, but serum‐derived immunoglobulin 
therapy with specific titers against PcrV also has great potential as effective immunotherapeu‐
tic tool against lethal P. aeruginosa infections.
8. Conclusions
In this review, we summarize the current status of research on the pathogenesis and treatment 
of P. aeruginosa infections from the viewpoint of acute and chronic infections. First, there are 
two phenotypes of P. aeruginosa strains: one causes acute types of infection, whereas the other 
causes chronic types of infection. Genomic level differences exist between these two pheno‐
types. In the course of evolution, acquisition of virulence gene cassettes, especially PAPI‐2, 
created subtypes with increasing toxicity. Second, exposure to antibiotics enhances their 
drug resistance together with a loss of cytotoxicity and antigenicity that can be targeted by 
host immunity. Third, some mutant cytotoxic and drug‐resistant P. aeruginosa strains may be 
involved in acute exacerbation of chronic infectious diseases. The lifespan of patients with CF 
has improved via various medical advances. Rather than focusing on eradication of infectious 
pathogens, prophylaxis against lethal pathogenic factors to avoid acute  exacerbation during 
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the chronic infection state should probably be given more priority at present. Currently, the 
monoclonal antibody strategies that are used against bacterial infections have not yet reached 
the level of practical application that is found in cancer therapy. The on‐going challenge for 
anti‐PcrV immunotherapy is realizing its potential to improve the clinical outcome of P. aeru‐
ginosa infections occurring in patients with CF.
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